Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer.
Roca E, Pennella E, Sardi M, Carraro S, Barugel M, Milano C, Fiorini A, Giglio R, Gonzalez G, Kneitschel R, Aman E, Jarentchuk A, Blajman C, Nadal J, Santarelli MT, Navigante A. Roca E, et al. Among authors: nadal j. Eur J Cancer. 1996 Mar;32A(3):429-32. doi: 10.1016/0959-8049(95)00524-2. Eur J Cancer. 1996. PMID: 8814686 Clinical Trial.
Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85).
Chacon R, Romero Acuña L, Blajman C, Galvez C, Bruno M, Romero A, Chiessa G, Bader M, Schwan R, Albera C, Santarelli MT, Sousa Martínez F, Nadal J, Viniegra M. Chacon R, et al. Among authors: nadal j. Br J Cancer. 1997;76(4):545-50. doi: 10.1038/bjc.1997.423. Br J Cancer. 1997. PMID: 9275035 Free PMC article. Clinical Trial.
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro L, Burotto M, Klingbiel D, Messeri D, Alexandrou A, Trask P, Fredriksson J, Machackova Z, Stamatovic L; PHranceSCa study group. O'Shaughnessy J, et al. Eur J Cancer. 2021 Jul;152:223-232. doi: 10.1016/j.ejca.2021.03.047. Epub 2021 Jun 16. Eur J Cancer. 2021. PMID: 34147014 Free article. Clinical Trial.
Breast Cancer in Young Women Presents With More Aggressive Pathologic Characteristics: Retrospective Analysis From an Argentine National Database.
Fabiano V, Mandó P, Rizzo M, Ponce C, Coló F, Loza M, Loza J, Amat M, Mysler D, Costanzo MV, Nervo A, Nadal J, Perazzo F, Chacón R; RCM Database Contributors4. Fabiano V, et al. Among authors: nadal j. JCO Glob Oncol. 2020 Apr;6:639-646. doi: 10.1200/JGO.19.00228. JCO Glob Oncol. 2020. PMID: 32315233 Free PMC article.
Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes.
Bruno L, Ostinelli A, Waisberg F, Enrico D, Ponce C, Rivero S, Blanco A, Zarba M, Loza M, Fabiano V, Amat M, Pombo MT, Noro L, Chacón M, Coló F, Chacón R, Nadal J, Nervo A, Costanzo V. Bruno L, et al. Among authors: nadal j. JCO Precis Oncol. 2022 Mar;6:e2100140. doi: 10.1200/PO.21.00140. JCO Precis Oncol. 2022. PMID: 35235412
In-Depth Analysis of the Peripheral Immune Profile of HER2+ Breast Cancer Patients on Neoadjuvant Treatment with Chemotherapy Plus Trastuzumab Plus Pertuzumab.
Pesce Viglietti AI, Bordignon MB, Ostinelli A, Rizzo MM, Cueto G, Sanchez MB, Perazzo F, Amat M, Coló F, Costanzo MV, Nervo A, Nadal J, Crimi G, Mc Lean I, Spengler EA, Mordoh J, Mandó P, Levy EM. Pesce Viglietti AI, et al. Among authors: nadal j. Int J Mol Sci. 2024 Aug 27;25(17):9268. doi: 10.3390/ijms25179268. Int J Mol Sci. 2024. PMID: 39273217 Free PMC article.
545 results